Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cb9f654ff-d5ftd Total loading time: 0 Render date: 2025-08-09T13:58:31.520Z Has data issue: false hasContentIssue false

Chapter 14 - Stroke after discontinuation of preventive medications

from Section III - Iatrogenic ischemic strokes: other causes

Published online by Cambridge University Press:  20 October 2016

By
Jelle Demeestere  and
Vincent Thijs
Edited by
Alexander Tsiskaridze ,
Arne Lindgren  and
Adnan I. Qureshi
Alexander Tsiskaridze
Affiliation:
Sarajishvili Institute of Neurology, Tblisi State University, Georgia
Arne Lindgren
Affiliation:
Department of Neurology, University Hospital Lund, Sweden
Adnan I. Qureshi
Affiliation:
Department of Neurology, University of Minnesota
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Chapter
Information
Treatment-Related Stroke
Including Iatrogenic and In-Hospital Strokes
 , pp. 144 - 154
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Vane, J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231:232–5.CrossRefGoogle ScholarPubMed
Evangelista, V, Manarini, S, Di Santo, A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res. 1998; 593–5.CrossRefGoogle Scholar
Bjornsson, T D, Schneider, D E, Berger, H. Aspirin aetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther. 1989; 250:154–61.Google ScholarPubMed
De Schryver, E L L M, van Gijn, J, Kappelle, L J, Koudstaal, P J, Algra, A. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol. 2005;252:1316–21.CrossRefGoogle ScholarPubMed
Kovich, O, Clark, C O. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. J Am Acad Dermatol. 2003; 48:233–7.CrossRefGoogle ScholarPubMed
Sibon, I, Orgogozo, J-M. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004; 62:1187–9.CrossRefGoogle ScholarPubMed
Maulaz, A B, Bezerra, D C, Michel, P, Bogousslavsky, J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005; 62:1217–20.CrossRefGoogle Scholar
Broderick, J P, Bonomo, J B, Kissela, B M, et al. Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke. 2011; 42:2509–14.CrossRefGoogle ScholarPubMed
Watanabe, H, Morimoto, T, Natsuaki, M, et al. Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: Observations from the CREDO-Kyoto Registry Cohort-2. PLoS One. 2015; 10(4):e0124314.CrossRefGoogle ScholarPubMed
Rossini, R, Musumeci, G, Capodanno, D, et al. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost. 2015; 113(2):272–82.Google ScholarPubMed
Burger, W, Chemnitius, J M, Kneissl, G D, Rücker, G. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks ater its perioperative withdrawal versus bleed risks with its continuation – review and meta-analysis. J Int Med. 2005; 257:399–414.CrossRefGoogle Scholar
García Rodríguez, L A, Soriano, L C, Hill, C, Johansson, S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011; 76:740–6.CrossRefGoogle ScholarPubMed
Weimar, C, Cotton, D, Sha, N, et al. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. Cerebrovasc Dis. 2013; 35:538–43.CrossRefGoogle ScholarPubMed
Lee, J, Kim, J K, Kim, J H, et al. Recovery time of platelet function after aspirin withdrawal. Curr Ther Res Clin Exp. 2014; 76:26–31.CrossRefGoogle ScholarPubMed
Le Manach, Y, Kahn, D, Bachelot-Loza, C, et al. Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery. PLoS One. 2014; 9(8):e104491.CrossRefGoogle ScholarPubMed
Aguejouf, O, Belougne-Malfatti, E, Doutremepuich, F, Belon, P, Doutremepuich, C. Thromboembolic complications several days after a single-dose administration of aspirin. Thromb Res. 1998; 89(3):123–7.CrossRefGoogle ScholarPubMed
Doutremepuich, C, Aguejouf, O, Eizayaga, F X, Desplat, V. Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition? Pathophysiol Haemost Thromb. 2007; 36:40–4.CrossRefGoogle ScholarPubMed
Aguejouf, O, Eizayaga, F, Desplat, V, Belon, P, Doutremepuich, C. Prothrombotic and hemorrhagic effects of aspirin. Clin Appl Thromb Hemost. 2009; 15(5):523–8.CrossRefGoogle ScholarPubMed
Vial, J H, McLeod, L J, Roberts, M S. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostatglandin Thromboxane Leukot Res. 1991; 21:157–60.Google Scholar
Moussa, S A, Forsythe, M S, Bozarth, J M, Reilly, T M. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology. 1993; 83:367–73.Google Scholar
Armstrong, M J, Gronseth, G, Anderson, D C, et al. Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013; 80:2065–9.CrossRefGoogle Scholar
Mantz, J, Samama, C M, Tubach, F, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: The multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. Br J Anaesth. 2011; 107(6):899–910.CrossRefGoogle ScholarPubMed
Dorsam, R T, Kunapuli, S P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004; 113(3):340–5.CrossRefGoogle ScholarPubMed
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348(9038):1329–39.Google Scholar
Diehl, P, Halscheid, C, Olivier, C, et al. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol. 2011; 100:765–71.CrossRefGoogle ScholarPubMed
Sambu, N, Warner, T, Curzen, N. Clopidogrel withdrawal: is there a “rebound” phenomenon? Thromb Haemost. 2011; 105:211–20.CrossRefGoogle Scholar
Collet, J-P, Montalescot, G, Steg, P G, et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis. 2009; 102:485–96.CrossRefGoogle ScholarPubMed
Geraghty, O C, Paul, N L M, Chandratheva, A, Rothwell, P M. Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. Neurology. 2010; 74:1891–6.CrossRefGoogle ScholarPubMed
Ford, I, Scott, N W, Herd, V, et al. A randomized controlled trial of platelet activity before and after cessation of clopidogrel therapy in patients with stable cardiovascular disease. J Am Coll Cardiol. 2014; 63:233–9.CrossRefGoogle ScholarPubMed
Rossen, J D, Chalouhi, N, Wassef, S N, et al. Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. J Neurosurg. 2012; 117:929–33.CrossRefGoogle ScholarPubMed
Fiedler, A K, Mehilli, J, Kufner, S, et al. Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Thromb Haemost. 2014; 111:1041–9.CrossRefGoogle ScholarPubMed
Mauri, L, Kereiakes, D J, Yeh, R W, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;Nov 16 (Epub ahead of print).CrossRefGoogle Scholar
Vongpatanasin, W, Hillis, L D, Lange, R A. Prosthetic heart valves. N Engl J Med. 1996; 335:407–16.CrossRefGoogle ScholarPubMed
The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J. 2010; 31:2369–429.Google Scholar
Douketis, J D, Berger, P B, Dunn, A S, et al. The perioperative management of antithrombotic therapy. American College of Chest Physicians evidence-based clinicial practice guidelines (8th edition). Chest. 2008; 133:299–339S.CrossRefGoogle Scholar
Di Biase, L, Burkhardt, J D, Santangeli, P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management. Results from the role of coumadin in preventing thromboembolism in atrial fibrillation patients undergoing catheter ablation (COMPARE) randomized trial. Circulation. 2014; 129:2638–44.CrossRefGoogle ScholarPubMed
Fang, M C, Go, A S, Chang, Y, Borowsky, L H, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010; 3:624–31.CrossRefGoogle ScholarPubMed
Tulner, L R, Van Campen, J P C M, Kuper, I M J A, et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation. A prospective, descriptive study. Drugs Aging. 2010; 27(1):39–50.CrossRefGoogle ScholarPubMed
Blacker, D J, Wijdicks, E F M, McClelland, R L. Stroke risk in anticoagulated patients with atrial fibrillation. Neurology. 2003; 61:964–8.CrossRefGoogle ScholarPubMed
Raunsø, J, Selmer, C, Olesen, J B, et al. Increased short-term riks of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J. 2012; 33(15):1886–92.CrossRefGoogle ScholarPubMed
Di Biase, L, Gaita, F, Toso, E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm. 2014; 11(5):791–8.CrossRefGoogle ScholarPubMed
Garcia, D A, Regan, S, Henault, L E, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008; 168(1):63–9.CrossRefGoogle ScholarPubMed
Cundiff, D K. Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med. 2008; 10(11):258.Google ScholarPubMed
Genewein, U, Haeberli, A, Straub, P W, Beer, J H. Rebound after cessation of oral anticoagulant therapy: The biochemical evidence. Br J Haematol. 1996;92:479–85.CrossRefGoogle ScholarPubMed
Reddy, V Y, Sievert, H, Halperin, J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: A randomized clinical trial. JAMA. 2014; 312(19):1988–98.CrossRefGoogle ScholarPubMed
Bai, R, Horton, R P, Di Biase, L, et al. Intraprocedural and long-term incomplete occlusion of the left atrial appendage following placement of the Watchman device: A single center experience. J Cardiovasc Electrophysiol. 2012; 23(5):455–61.CrossRefGoogle ScholarPubMed
Chatterjee, S, Sardar, P, Giri, J S, Ghosh, J, Mukherjee, D. Treatment discontinuations with new oral agents for long-term anticoagulation: Insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc. 2014; 89(7):896–907.CrossRefGoogle ScholarPubMed
Zalesak, M, Siu, K, Francis, K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013; 6(5):567–74.CrossRefGoogle ScholarPubMed
Nascimento, T, Birnie, D H, Healey, J S, et al. Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey. Can J Cardiol. 2014; 30(2):231–6.CrossRefGoogle ScholarPubMed
Watanabe, M, Siddiqui, F M, Qureshi, A I. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocrit Care. 2012; 16:203–9.CrossRefGoogle ScholarPubMed
Patel, M R, Hellkamp, A S, Lokhnygina, Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013; 61(6):651–8.CrossRefGoogle Scholar
Reynolds, M R. Discontinuation of rivaroxaban: Filling in the gaps. J Am Coll Cardiol. 2013;61(6):659–60.CrossRefGoogle ScholarPubMed
Granger, C B, Alexander, J H, McMurray, J J, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981–92.CrossRefGoogle ScholarPubMed
Granger, C B, Lopes, R D, Hanna, M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Am Heart J. 2015; 169(1):25–30.CrossRefGoogle ScholarPubMed
Connolly, S J, Ezekowitz, M D, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139–51.CrossRefGoogle ScholarPubMed
Giugliano, R P, Ruff, C T, Braunwald, E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093–104.CrossRefGoogle ScholarPubMed
Davignon, J, Leiter, L A. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag. 2005; 1(1):29–40.CrossRefGoogle ScholarPubMed
Amarenco, P, Bogousslavsky, J, Callahan, A, et al. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators. N Eng J Med. 2006; 355:549–59.Google ScholarPubMed
Colvicchi, F, Bassi, A Santini, M, Caltagirone, C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke. 2007; 38:2652–7.Google Scholar
Blanco, M, Nombela, F, Castellanos, M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007; 69:904–10.CrossRefGoogle ScholarPubMed
Fuentes, B, Martínez-Sánchez, P, Díez-Tejedor, E. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis. 2009; 27(1):126–33.CrossRefGoogle ScholarPubMed
Endres, M. Statins and stroke. J Cereb Blood Flow Metab. 2005; 25(9):1093–110.CrossRefGoogle ScholarPubMed
Li, J-J, Li, Y-S, Chu, J-M, et al. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clinica Chimica Acta. 2006; 366:269–73.CrossRefGoogle ScholarPubMed
Rosengarten, B, Auch, D, Kaps, M. Effects of initiation and acute withdrawal of statins on the neurovascular coupling mechanism in healthy, normocholesterolemic humans. Stroke. 2007; 38:3193–7.CrossRefGoogle ScholarPubMed
Dowlatshahi, D, Demchuk, A M, Fang, J, et al. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke. 2012; 43:1518–23.CrossRefGoogle ScholarPubMed
Robinson, T G, Potter, J F, Ford, G A, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): A prospective, randomised, open, blinded-endpoint trial. Lancet Neurol. 2010; 9(8):767–75.CrossRefGoogle ScholarPubMed
Bath, et al. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): A partial-factorial randomised controlled trial. Lancet. 2014; 22 October: Epub ahead of print.Google Scholar
Baird, T A, Parsons, M W, Phan, T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003; 34:2208–14.CrossRefGoogle ScholarPubMed
Rosso, C, Corvol, J C, Pires, C, et al. Intensive versus subcutaneous insulin in patients with hyperacute stroke: Results from the randomized INSULINFARCT trial. Stroke. 2012; 43(9):2343–9.CrossRefGoogle ScholarPubMed

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×